Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.91 and traded as high as $4.78. Cumberland Pharmaceuticals shares last traded at $4.76, with a volume of 25,526 shares traded.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Stock Down 0.6 %

The company's 50 day simple moving average is $4.86 and its 200-day simple moving average is $3.00. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The firm has a market cap of $69.00 million, a P/E ratio of -6.42 and a beta of -0.24.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The firm had revenue of $10.44 million during the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP raised its holdings in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,649 shares of the specialty pharmaceutical company's stock after acquiring an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 15.51% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.